Work

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.4535

Authors: R. A. Figlin, G. V. Kondagunta, S. Yazji, R. J. Motzer, R. M. Bukowski

Institutions: Cleveland Clinic, Memorial Sloan Kettering Cancer Center, University of California, Los Angeles

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597686203

Cites:

Cited by: 31

Related to: 10